

# Clinical Oversight Review Board (CORB) Criteria for Prescribing Ocrelizumab (Ocrevus)

Non-Formulary **ocrelizumab (Ocrevus)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

**Initiation (new start) criteria, criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:** Non-formulary **ocrelizumab (Ocrevus)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a Neurologist
- Patient has a diagnosis of Multiple Sclerosis
- Patient has an allergy to rituximab or a rituximab biosimilar product